|
Status |
Public on Jun 18, 2018 |
Title |
Physiologic expression of Srsf2(P95H) causes myeloid expansion, impaired competitive stem cell function and initiates the myeloproliferative/myelodysplastic syndrome in vivo. |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing Other
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
29903888 |
|
Submission date |
Jun 09, 2017 |
Last update date |
Jul 25, 2021 |
Contact name |
Alistair Morgan Chalk |
E-mail(s) |
achalk@svi.edu.au, alistair.chalk@gmail.com
|
Organization name |
St Vincent's Institute of Medical Research
|
Department |
Stem Cell Regulation Unit
|
Lab |
Walkley
|
Street address |
9 Princes st, Fitzroy
|
City |
Melbourne |
State/province |
VIC |
ZIP/Postal code |
3065 |
Country |
Australia |
|
|
Platforms (2) |
GPL19057 |
Illumina NextSeq 500 (Mus musculus) |
GPL21273 |
HiSeq X Ten (Mus musculus) |
|
Samples (14)
|
GSM2655966 |
Whole Bone Marrow in vivo tamoxifen treated R26CreERT2 Srsf2 P95H from animal 108 |
GSM2655967 |
Ear in vivo tamoxifen treated R26CreERT2 Srsf2 P95H from animal 108 |
GSM2655968 |
Whole Bone Marrow in vivo tamoxifen treated R26CreERT2 Srsf2 P95H from animal 136 |
GSM2655969 |
Ear in vivo tamoxifen treated R26CreERT2 Srsf2 P95H from animal 136 |
GSM2655970 |
Whole Bone Marrow in vivo tamoxifen treated R26CreERT2 Srsf2 P95H from animal 54 |
GSM2655971 |
Ear in vivo tamoxifen treated R26CreERT2 Srsf2 P95H from animal 54 |
GSM2655972 |
Whole bone marrow in vivo tamoxifen treated R26CreERT2 Srsf2 P95H |
GSM2655973 |
Whole bone marrow in vivo tamoxifen treated R26CreERT2 Srsf2 WT |
GSM2811301 |
Lin-/cKit+/eYFP+ cells from whole bone marrow in vivo tamoxifen treated hScl-CreERT R26eYFP Srsf2 +/+_1 |
GSM2811302 |
Lin-/cKit+/eYFP+ cells from whole bone marrow in vivo tamoxifen treated hScl-CreERT R26eYFP Srsf2 +/+_2 |
GSM2811303 |
Lin-/cKit+/eYFP+ cells from whole bone marrow in vivo tamoxifen treated hScl-CreERT R26eYFP Srsf2 +/+_3 |
GSM2811304 |
Lin-/cKit+/eYFP+ cells from whole bone marrow in vivo tamoxifen treated hScl-CreERT R26eYFP Srsf2 P95H/+_1 |
GSM2811305 |
Lin-/cKit+/eYFP+ cells from whole bone marrow in vivo tamoxifen treated hScl-CreERT R26eYFP Srsf2 P95H/+_2 |
GSM2811306 |
Lin-/cKit+/eYFP+ cells from whole bone marrow in vivo tamoxifen treated hScl-CreERT R26eYFP Srsf2 P95H/+_3 |
|
This SuperSeries is composed of the following SubSeries: |
GSE99850 |
Physiologic expression of Srsf2(P95H) causes myeloid expansion, impaired competitive stem cell function and initiates the myeloproliferative/myelodysplastic syndrome in vivo [WES] |
GSE99851 |
Physiologic expression of Srsf2(P95H) causes myeloid expansion, impaired competitive stem cell function and initiates the myeloproliferative/myelodysplastic syndrome in vivo [RNA-seq] |
GSE104976 |
Physiologic expression of Srsf2(P95H) causes myeloid expansion, impaired competitive stem cell function and initiates the myeloproliferative/myelodysplastic syndrome in vivo [RNA-seq2] |
|
Relations |
BioProject |
PRJNA389781 |